Drug Pricing
Commentary
Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Blog
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Commentary
Trump Should Support Effective Drug Policy Reforms Not The MFN Gimmick
The Trump Administration has announced its desire to impose price controls on drugs – officially called a most favored nation (MFN) policy. Essentially, the policy sets the price for the targeted drugs at the lowest price in other industrialized countries. The president’s justification for the MFN is simple: Americans are ...
Commentary
Why sunblock in the U.S. is so much worse than in the E.U.
One in five Americans will develop skin cancer by age 70. Yet regulators in the United States have not approved sunscreens that can more effectively prevent the disease. Such safetyism makes little sense. Americans receive more diagnoses for skin cancer than for all other forms of cancer combined. It’s long ...
Blog
Read about the push for drug price controls
Trump and Biden Agree on Drug Pricing
Patients will pay dearly, as Michael Baker and Douglas Holtz-Eakin explain in two recent pieces for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems. Biden signed the Inflation Reduction Act into law in 2022. It directs the feds to “negotiate” prices for a steadily increasing number of ...
Commentary
Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers
Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
Commentary
A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis
Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary
Congress Should Not Impose Foreign Price Controls On Innovative Drugs
Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. ...
Commentary
Medicaid Is Not A Test Lab For Foreign Price Controls
In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Trump Should Support Effective Drug Policy Reforms Not The MFN Gimmick
The Trump Administration has announced its desire to impose price controls on drugs – officially called a most favored nation (MFN) policy. Essentially, the policy sets the price for the targeted drugs at the lowest price in other industrialized countries. The president’s justification for the MFN is simple: Americans are ...
Why sunblock in the U.S. is so much worse than in the E.U.
One in five Americans will develop skin cancer by age 70. Yet regulators in the United States have not approved sunscreens that can more effectively prevent the disease. Such safetyism makes little sense. Americans receive more diagnoses for skin cancer than for all other forms of cancer combined. It’s long ...
Read about the push for drug price controls
Trump and Biden Agree on Drug Pricing
Patients will pay dearly, as Michael Baker and Douglas Holtz-Eakin explain in two recent pieces for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems. Biden signed the Inflation Reduction Act into law in 2022. It directs the feds to “negotiate” prices for a steadily increasing number of ...
Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers
Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis
Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Congress Should Not Impose Foreign Price Controls On Innovative Drugs
Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. ...
Medicaid Is Not A Test Lab For Foreign Price Controls
In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
